Cord blood trial aims to beat long COVID fatigue

NCT ID NCT07184385

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 27 times

Summary

This phase 3 study tests if an infusion of human umbilical cord blood (REGENECYTE) can reduce fatigue in people with Long COVID. About 60 adults with post-COVID condition will receive either the cord blood infusion or a placebo. The main goal is to see if fatigue improves, while also checking for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.